These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 23562987

  • 61. Infliximab treatment in psoriatic arthritis: our experience.
    Rioda WT, Adorni G.
    Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
    [Abstract] [Full Text] [Related]

  • 62. Potential use of TNF-α inhibitors in systemic sclerosis.
    Murdaca G, Spanò F, Contatore M, Guastalla A, Puppo F.
    Immunotherapy; 2014 Aug; 6(3):283-9. PubMed ID: 24762073
    [Abstract] [Full Text] [Related]

  • 63. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
    Licastro F, Chiappelli M, Ianni M, Porcellini E.
    Int J Immunopathol Pharmacol; 2009 Aug; 22(3):567-72. PubMed ID: 19822073
    [Abstract] [Full Text] [Related]

  • 64. Remission in psoriatic arthritis: is it possible and how can it be predicted?
    Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, Grier A, Molloy M, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ.
    Arthritis Res Ther; 2010 Aug; 12(3):R94. PubMed ID: 20482783
    [Abstract] [Full Text] [Related]

  • 65. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
    Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J.
    Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
    [Abstract] [Full Text] [Related]

  • 66. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 67. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A, Gheorghiu AM, Aramă V, Bumbăcea D, Dobrotă R, Oneaţă R, Pintilie S, Milicescu M, Ancuţa I, Martin A, Sasu M, Ciofu C, Macovei L, Stoica V, Bojincă M, Mihai C.
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [Abstract] [Full Text] [Related]

  • 68. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML.
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [Abstract] [Full Text] [Related]

  • 69. Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.
    Bergman M, De G, Ganguli A, Signorovitch J, Bao Y.
    J Med Econ; 2015 Jan; 18(1):37-44. PubMed ID: 24841451
    [Abstract] [Full Text] [Related]

  • 70. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
    Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O.
    J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
    [Abstract] [Full Text] [Related]

  • 71. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 72. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM, Marchesoni A, Lubrano E.
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [Abstract] [Full Text] [Related]

  • 73. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety.
    Lemos LL, de Oliveira Costa J, Almeida AM, Junior HO, Barbosa MM, Kakehasi AM, Acurcio FA.
    Rheumatol Int; 2014 Oct; 34(10):1345-60. PubMed ID: 24728068
    [Abstract] [Full Text] [Related]

  • 74. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study.
    Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, Uutela T, Puurtinen-Vilkki M, Arstila L, Blom M, Sokka T, Nordström D.
    Semin Arthritis Rheum; 2017 Jun; 46(6):732-739. PubMed ID: 28010883
    [Abstract] [Full Text] [Related]

  • 75. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
    Chen JS, Makovey J, Lassere M, Buchbinder R, March LM.
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):464-72. PubMed ID: 24022870
    [Abstract] [Full Text] [Related]

  • 76. [Biological agents in treatment of psoriatic arthritis].
    Lewicki M, Dutkiewicz B, Widuchowska M, Kucharz EJ.
    Pol Merkur Lekarski; 2008 Jul; 25(145):97-100. PubMed ID: 18839626
    [Abstract] [Full Text] [Related]

  • 77. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J, Sieper J, Weiß A, Zink A, Listing J.
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [Abstract] [Full Text] [Related]

  • 78. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
    Stober C, Ye W, Guruparan T, Htut E, Clunie G, Jadon D.
    Rheumatology (Oxford); 2018 Jan 01; 57(1):158-163. PubMed ID: 29077973
    [Abstract] [Full Text] [Related]

  • 79. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.
    J Manag Care Spec Pharm; 2014 Jul 01; 20(7):657-67. PubMed ID: 24967519
    [Abstract] [Full Text] [Related]

  • 80. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, Perricone R, Chimenti S, Chimenti MS.
    Dermatology; 2012 Jul 01; 225(4):312-9. PubMed ID: 23295383
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.